391 related articles for article (PubMed ID: 29105080)
1. Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis.
Zhu Z; Du S; Du Y; Ren J; Ying G; Yan Z
J Neurochem; 2018 Jan; 144(1):93-104. PubMed ID: 29105080
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
3. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Chen L; Li X; Liu L; Yu B; Xue Y; Liu Y
Oncol Rep; 2015 Mar; 33(3):1465-74. PubMed ID: 25585997
[TBL] [Abstract][Full Text] [Related]
4. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Rocha CR; Kajitani GS; Quinet A; Fortunato RS; Menck CF
Oncotarget; 2016 Jul; 7(30):48081-48092. PubMed ID: 27344172
[TBL] [Abstract][Full Text] [Related]
5. Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
Polewski MD; Reveron-Thornton RF; Cherryholmes GA; Marinov GK; Cassady K; Aboody KS
Mol Cancer Res; 2016 Dec; 14(12):1229-1242. PubMed ID: 27658422
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
7. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
[TBL] [Abstract][Full Text] [Related]
8. Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
Rocha CR; Garcia CC; Vieira DB; Quinet A; de Andrade-Lima LC; Munford V; Belizário JE; Menck CF
Cell Death Dis; 2014 Oct; 5(10):e1505. PubMed ID: 25356874
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.
Munoz JL; Rodriguez-Cruz V; Greco SJ; Ramkissoon SH; Ligon KL; Rameshwar P
Cell Death Dis; 2014 Mar; 5(3):e1145. PubMed ID: 24675463
[TBL] [Abstract][Full Text] [Related]
10. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
11. Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma.
Kim SS; Seong S; Lim SH; Kim SY
Biochem Biophys Res Commun; 2013 Nov; 440(4):658-63. PubMed ID: 24113378
[TBL] [Abstract][Full Text] [Related]
12. Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.
Anderson JC; Duarte CW; Welaya K; Rohrbach TD; Bredel M; Yang ES; Choradia NV; Thottassery JV; Yancey Gillespie G; Bonner JA; Willey CD
Radiother Oncol; 2014 Jun; 111(3):468-74. PubMed ID: 24813092
[TBL] [Abstract][Full Text] [Related]
13. The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells.
Dong F; Eibach M; Bartsch JW; Dolga AM; Schlomann U; Conrad C; Schieber S; Schilling O; Biniossek ML; Culmsee C; Strik H; Koller G; Carl B; Nimsky C
Neuro Oncol; 2015 Nov; 17(11):1474-85. PubMed ID: 25825051
[TBL] [Abstract][Full Text] [Related]
14. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
15. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.
Montaldi AP; Godoy PR; Sakamoto-Hojo ET
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():19-29. PubMed ID: 26520369
[TBL] [Abstract][Full Text] [Related]
16. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
17. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
[TBL] [Abstract][Full Text] [Related]
18. MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Xu P; Zhang G; Hou S; Sha LG
Biomed Pharmacother; 2018 Oct; 106():1419-1427. PubMed ID: 30119215
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production.
Oliva CR; Moellering DR; Gillespie GY; Griguer CE
PLoS One; 2011; 6(9):e24665. PubMed ID: 21931801
[TBL] [Abstract][Full Text] [Related]
20. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
